InspireMD Inc (NSPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InspireMD Inc (NSPR) has a cash flow conversion efficiency ratio of -0.135x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.63 Million) by net assets ($64.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
InspireMD Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how InspireMD Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NSPR liabilities breakdown for a breakdown of total debt and financial obligations.
InspireMD Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InspireMD Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cenit Co. Ltd
KQ:037760
|
0.001x |
|
OssDsign AB
ST:OSSD
|
-0.054x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
Mirza International Limited
NSE:MIRZAINT
|
0.020x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
|
Grand Hall Enterprise Co Ltd
TWO:8941
|
0.077x |
|
CLOUDR GROUP LTD.
F:H3L
|
N/A |
|
Sangji Caelum Inc
KQ:042940
|
-0.089x |
Annual Cash Flow Conversion Efficiency for InspireMD Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of InspireMD Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see NSPR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $36.09 Million | $-21.87 Million | -0.606x | -46.17% |
| 2023-12-31 | $39.50 Million | $-16.38 Million | -0.415x | +53.61% |
| 2022-12-31 | $17.39 Million | $-15.54 Million | -0.894x | -126.82% |
| 2021-12-31 | $33.53 Million | $-13.21 Million | -0.394x | +47.23% |
| 2020-12-31 | $12.16 Million | $-9.08 Million | -0.747x | +59.03% |
| 2019-12-31 | $5.38 Million | $-9.81 Million | -1.822x | -109.96% |
| 2018-12-31 | $8.76 Million | $-7.61 Million | -0.868x | +70.89% |
| 2017-12-31 | $2.73 Million | $-8.13 Million | -2.982x | -60.92% |
| 2016-12-31 | $4.04 Million | $-7.50 Million | -1.853x | -147.07% |
| 2015-12-31 | $-2.95 Million | $-11.60 Million | 3.936x | -43.34% |
| 2014-12-31 | $-2.79 Million | $-19.36 Million | 6.947x | +465.44% |
| 2013-12-31 | $5.42 Million | $-10.30 Million | -1.901x | -19.34% |
| 2012-12-31 | $5.39 Million | $-8.58 Million | -1.593x | 0.00% |
| 2011-12-31 | $5.39 Million | $-8.58 Million | -1.593x | -119.31% |
| 2010-12-31 | $-2.30K | $-18.98K | 8.249x | 0.00% |
| 2009-12-31 | $-2.30K | $-18.98K | 8.249x | +1774.80% |
| 2008-12-31 | $1.68K | $-825.00 | -0.493x | -- |
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding car… Read more